GERMANY BIOTECH PITCH DECK AGENCY
Biotech Pitch Deck Design Agency Germany That Turns Max Planck Science Into Raised Capital
German Life Sciences Research Deserves Global Capital Access
BioNTech, founded in Mainz and listed on Nasdaq, transformed global perception of German biotech by developing the world's first mRNA vaccine at scale, proving Germany's research ecosystem can produce commercially transformative products, not just important discoveries. This heritage built a knowledge and talent base across Mainz, Frankfurt, and the Rhine-Main corridor, elevating German biotech for Wellington Partners, Forbion Capital, and MIG Fonds.
German biotech has three exit pathways, each demanding a different deck. EMA approval followed by European out-licensing requires clinical data quality and patent exclusivity emphasis. Acquisition by Bayer AG, Merck KGaA, or Boehringer Ingelheim requires pipeline fit and Phase II data over Phase III completion. Frankfurt TecDAX listing requires structuring for institutional investors who assess biotech risk differently than Nasdaq. These pathways contradict each other: what wins Bayer discussions undermines an IPO roadshow, and what wins Wellington Partners fails for Forbion.
Slidey is the biotech pitch deck design agency Germany founders trust to resolve this three-exit challenge, building a modular exit architecture that presents each pathway's emphasis to the right investor audience within one coherent pipeline value story.
.png)
Two German Advantages That International Biotech Investors Rarely See
Max Planck's curiosity-driven basic research produces novel biology rather than incremental improvement. Helmholtz's 19 centres, including DKFZ, Helmholtz Munich, and DZNE, offer clinical-adjacent patient access. Our biotechnology startup pitch deck consultants Germany team positions each origin differently.
UK biotech now navigates MHRA and EMA separately, adding cost and delay. German biotech submits one EU-wide CTA, engages CHMP directly, and reaches all EU markets without the dual-jurisdiction burden UK competitors now carry.
GERMAN BIOTECH HAS A CORPORATE PHARMA ADVANTAGE NO OTHER COUNTRY MATCHES
Bayer evaluates cardiovascular, oncology, women's health, and ophthalmology assets with Phase II data before co-development talks. Our biotech pitch deck design service Germany team builds separate evaluation sections since Merck KGaA's Life Science and Healthcare divisions differ entirely.
Paul-Ehrlich-Institut is Europe's specialist ATMP authority, accelerating gene and cell therapy development. Forbion and Boehringer Ingelheim Venture Fund apply manufacturing complexity frameworks, so Slidey builds a dedicated readiness section standard biotech decks skip entirely.
.png)
German Biotech Valuation Follows a Different Mathematical Logic
Wellington Partners, Forbion Capital, MIG Fonds, and HBM Partners apply rNPV pipeline valuation with more conservative probability-of-success assumptions than US biotech investors. Funds like Atlas Venture use industry-standard benchmarks near 9 percent for oncology approval, while German and pan-European investors apply assumptions 20 to 30 percent more conservative, reflecting Europe's historically lower conditional approval rates. A founder presenting three oncology assets using US benchmarks will see a 25 to 40 percent valuation gap emerge in the first meeting, killing momentum before term sheet. Our biotech pitch deck experts Germany team structures pipeline sections using European probability benchmarks from the outset to eliminate this gap. Results below are actual raises.
.avif)
Raised
.avif)
Raised
.avif)
Raised
.avif)
Raised
The Six Stages of a German Biotech Deck
German Biotech Discovery
We identify your pipeline stage, research origin, Go-Bio status, and EMA pathway.
EMA Clinical Trial Architecture
We structure the single EU-wide CTA as a trial execution efficiency advantage.
.svg)
Orphan Drug Designation Architecture
We frame COMP review as unmet need validation and exclusivity moat.
.svg)
Sartorius Bioprocess Partnership Positioning
We show manufacturing readiness using industry-standard biologics equipment and methods.
.svg)
Bayer Out-Licensing Deal Architecture
We map therapeutic fit, data quality, and peak sales potential for BD&L.
.svg)
Frankfurt IPO Pathway Architecture
We benchmark clinical stage against TecDAX and Prime Standard readiness.
German Biotech Complexity Deserves Pricing That Reflects Real Work
Built for early-stage German biotech at preclinical or Phase I stage raising from Go-Bio, MIG Fonds, or Wellington Partners with Max Planck or Helmholtz origin.
$800
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
German Biotech Founders Start Here Regardless of Pipeline Stage
.png)
German Biotech Pipeline Decks That Cleared Wellington Partners Investment Committees
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.svg)